30
Aug 2026
In a community-based trial in rural China, an intensive blood-pressure lowering intervention reduced the incidence of dementia compared with usual care, according to results from the China Rural Hypertension Control Program presented in a Hot Line session today at ESC Congress 2026.
30
Aug 2026
Catheter ablation for atrial fibrillation (AF) did not significantly improve AF-related quality of life compared with a sham procedure, despite reducing AF recurrence.
30
Aug 2026
A systematic review of 1,000 screened records identified only three eligible studies examining administration timing for semaglutide, and none directly compared different days of the week or assessed tirzepatide timing. The limited evidence suggests flexible dosing may support adherence and tolerability without compromising glycemic control or weight loss, but these findings rely largely on indirect evidence and expert opinion rather than direct comparative trials.
30
Aug 2026
For many adolescents and young adults, life revolves around new experiences, greater independence, and new relationships.
30
Aug 2026
A TAVI-first strategy was noninferior to a PCI-first strategy after one years' follow-up, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.
30
Aug 2026
A single dose of psilocybin produced a lasting increase in sociability for at least two weeks in Cntnap2-knockout mice with social deficits, while it did not enhance sociability overall in mice with normal social behavior. The effect required 5-HT2A receptor activation and persisted when psilocybin was administered under light anesthesia, suggesting that wakefulness during the drug’s acute effects was not necessary for this behavioral response.
30
Aug 2026
Early initiation of statins after diagnosis of type 2 diabetes was associated with a lower risk of dementia, according to a study presented today at ESC Congress 2026 and published in The Lancet Regional Health – Europe.
30
Aug 2026
The oral relaxin agonist, AZD5462, improved cardiac function in patients with chronic heart failure, according to results presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in Circulation.
30
Aug 2026
Metformin did not significantly affect the risk of cardiovascular outcomes in patients with heart failure with reduced ejection fraction and diabetes or at risk of diabetes.
30
Aug 2026
In patients with heart failure, hydralazine with isosorbide dinitrate did not significantly improve the incidence of death or heart failure events and treatment discontinuation rates were high.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
